Skip to content

Effect of Latanoprost on Optic Nerve Perfusion

Optic Nerve Head Perfusion Following Treatment with Latanoprost 0.005% in Primary Open Angle Glaucoma: an Optical Coherence Tomography Angiography Study

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06629129
Enrollment
46
Registered
2024-10-08
Start date
2024-06-24
Completion date
2024-08-30
Last updated
2024-10-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Treatment Outcome

Keywords

Open angle glaucoma, OCTA, RNFL

Brief summary

46 eyes of 23 patients have been treated with topical Latanoprost 0.005 %. visual field was performed on all eyes. NFLT was measured using OCT. Radial peripapillary capillary (RPC) vascular density was measured using OCTA . mean ocular perfusion pressure (MOPP), and RPC vascular density were measured before and after treatment BY 2-3 MONTHS

Detailed description

All patients had bilateral primary open angle glaucoma diagnosed by increased IOP, visual field changes, and defective nerve fiber layer thickness (NFLT) on OCT examination. All patients treated with topical Latanoprost 0.005% (XalatanTM, 2.5 ml eye drops, Pfizer) Inclusion criteria: age > 20 years, newly diagnosed patients with POAG. The exclusion criteria included optic nerve lesions other than glaucomatous changes, All patients completed their ophthalmic examination to detect BCVA, cycloplegic refraction, and anterior segment examination , IOP measuring by applanation tonometer, and indirect ophthalmoscope fundus examination. Visual field testing. The thickness of NFL around the disc was evaluated using spectral domain optical coherence tomography (OCT) Optovue octa was used to quantify the density of the radial peripapillary capillary (RPC) vessels. This study employed software to quantify the capillary (microvasculature) density in both the entire image and in the peripapillary region specifically the superior, nasal, inferior, and temporal quadrants. The mean arterial blood pressure (MAP) was determined by adding the diastolic blood pressure (DBP) to one third of the difference between systolic blood pressure and the diastolic blood pressure. All eyes were treated with topical latanoprost 0.005% (XalatanTM, 2.5 ml eye drops, Pfizer) with dose of one drop at bedtime. IOP, MOPP, NFLT, and RPC vascular density were measured before the beginning of treatment and 1 and 3 months after treatment.

Interventions

MEAN OCULAR PERFUSION PRESSURE WAS MEASURED AND CORRELATED TO THE IOP AND OPTIC NERVE PERFUSION IN RESPONSE TO LATANOPROST TREATMENT

Sponsors

Zagazig University
Lead SponsorOTHER_GOV

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No

Inclusion criteria

POAG with no past ocular surgery or laser retinal treatment. No previous anti-glaucoma medications

Exclusion criteria

* optic nerve lesions other than glaucoma

Design outcomes

Primary

MeasureTime frameDescription
quantify the peri papillary capillary (microvasculature) density using OCTA3 monthsquantify the capillary (microvasculature) density in both the entire image and in the peripapillary region specifically the superior, nasal, inferior, and temporal quadrants

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026